7 travaux publiés en 2020 dans le domaine des hépatites virales B et C
Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
De Ledinghen V & al.
J Viral Hepat. 2020 Oct;27(10):964-973. doi: 10.1111/jvh.13321. Epub 2020 May 21.
Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort).
Barré T & al.
J Viral Hepat. 2020 Dec;27(12):1473-1483.doi: 10.1111/jvh.13380. Epub 2020 Sep 8.
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
Mangia A &al.
J Liver Int. 2020 Aug;40(8):1841-1852. doi: 10.1111/liv.14537. Epub 2020 Jun 9.
Liver Cirrhosis in Chronic Hepatitis B Patients Is Associated with Genetic Variations in DNA Repair Pathway Genes.
Rybicka M & al.
Cancers (Basel). 2020 Nov 7;12(11):3295.doi: 10.3390/cancers12113295.
Personalized surveillance for hepatocellular carcinoma in cirrhosis using machine learning adapted to HCV Status.
Audureau E & al.
J Hepatol 2020 Dec;73(6):1434-1445. doi: 10.1016/j.jhep.2020.05.052.
Genetic variation in IL-10 influences the progression of hepatitis B infection.
Rybicka M & al.
Int J Infect Dis. 2020 Jul;96:260-265.doi: 10.1016/j.ijid.2020.04.079. Epub 2020 May 6.